Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guenter Stays Focused After Almirall's Annus Horribilis

Executive Summary

Peter Guenter, brought in from Sanofi to fix the problems at Almirall, is staying focused on 2018 as he outlines his plan to rebuild the Spanish company. Almirall will continue reallocating resources and seeking bolt-on deals to establish a sustainable dermatology business as it rolls out Skilarence and tildrakizumab in Europe.

You may also be interested in...



Good Prospects For Athenex/Almirall Following PhIII Actinic Keratosis Results

Two Phase III studies of KX2-391 to treat actinic keratosis of the face and scalp met their primary endpoint of 100% clearance. The treatment could prove more convenient than marketed therapies.

Almirall Knocked Back By US Woes, Could Affect Other Companies Too

Spain’s Almirall has suffered business setbacks in the US - including in its patient assistance program - that have forced the mid-sized drug maker to issue a profit warning, triggering of a sharp slide in its share price.

Pfizer, Fosun Partner BioNTech On mRNA COVID-19 Vaccine

BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.

Topics

Related Companies

UsernamePublicRestriction

Register

SC100460

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel